Content Services
- Technical Writing
- Training & eLearning
- Financial Reports
- Digital Marketing
- SEO & Content Optimization
Translation Services
- Video Localization
- Software Localization
- Website Localization
- Translation for Regulated Companies
- Interpretation
- Instant Interpreter
- Live Events
- Language Quality Services
Testing Services
- Functional QA & Testing
- Compatibility Testing
- Interoperability Testing
- Performance Testing
- Accessibility Testing
- UX/CX Testing
Solutions
- Translation Service Models
- Machine Translation
- Smart Onboarding™
- Aurora AI Studio™
Our Knowledge Hubs
- Positive Patient Outcomes
- Modern Clinical Trial Solutions
- Future of Localization
- Innovation to Immunity
- COVID-19 Resource Center
- Disruption Series
- Patient Engagement
- Lionbridge Insights
Life Sciences
- Pharmaceutical
- Clinical
- Regulatory
- Post-Approval
- Corporate
- Medical Devices
- Validation and Clinical
- Regulatory
- Post-Authorization
- Corporate
Banking & Finance
Retail
Luxury
E-Commerce
Games
Automotive
Consumer Packaged Goods
Technology
Industrial Manufacturing
Legal Services
Travel & Hospitality
SELECT LANGUAGE:
There are now more trials than ever that require trial participants to use computerized systems and digital health tools. Applications of these systems and devices aim to facilitate data collection in clinical trials and provide greater convenience for trial participants.
However, inadequate training on (and support with) these systems and tools may cause trial volunteers distress and burden. If left unaddressed, trial sponsors may see these results:
Providing trial participants with adequate training on computerized systems is critical to mitigating these risks. This blog outlines how such training has been addressed in recent industry and regulatory guidance.
The ICH E6 Good Clinical Practice (GCP) Guideline is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human volunteer participation.
The original guideline, dated 1996, was updated in 2016 (R2). It’s currently being revamped to R3, with the review process at the public consultation stage. The revamp is driven by changes in the clinical research environment since the guideline’s previous update, including increasing diversity of clinical trial designs and data sources that serve to support regulatory and health policy decision-making.
Section 2.12 (Records), E6 (R3) outlines the expectation to provide trial participants with computerized systems training. It states that, where equipment for data acquisition is provided to trial participants by the investigator, the investigator/institution should ensure that traceability is maintained and participants are provided with appropriate training (2.12.9 -c).
Likewise, Section 3.16 (Data and Records) states that, when using computerized systems in a clinical trial, trial sponsors should:
Provide guidance to trial participants, where relevant, on the expectations for data capture, data changes, data retention, and data disposal (3.16.1 -g)
Ensure that documented procedures and adequate training are in place to ensure the correct development, maintenance, and use of computerized systems in the trial. Notably, the attached caveat is that these requirements should be proportionate to the importance of the computerized system and the data or activities they’re expected to process (3.16.1 -w -ii).
More detailed guidance is provided in the new Section 4 (Data Governance ꟷ Investigator and Sponsor). This section focuses on systems and data that may impact the safety and rights of trial participants and reliability of trial results. It also covers the need for a comprehensive (risk-proportionate) approach to computerized systems and tools.
Section 4.3 (Computerised Systems) includes a separate sub-section on training. This sub-section reiterates the expectation of providing appropriate training for intended users (4.3.2). Additionally, it recommends involving representatives of intended participant populations and healthcare professionals when designing computerized systems(where relevant). This step helps ensure such systems are suitable for use by the intended user population.
Regulators, such as the EMA and U.S. FDA, support the critical importance of training trial participants on appropriate use of trial-enabling technologies. These regulators have set expectations in their various respective guidance documents. Their expectations cover a broad range of aspects around:
The table below provides a reference point highlighting some (non-exhaustive) examples.
Need language assistance for creating and translating participant training materials for your multi-regional clinical trial? Lionbridge has deep knowledge of life sciences translation services, clinical trial translation services, and eLearning. Contact us today to find out more about Lionbridge as a life sciences language service provider and start addressing your clinical trial translation needs.